IA
ENTA icon

IndexIQ Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

IndexIQ Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,563
Closed -$640K – 1372
2021
Q4 		$640K Sell
8,563
-553
-6% -$43.4K 0.02% 416
2021
Q3 		$518K Buy
9,116
+913
+11% +$45.1K 0.02% 525
2021
Q2 		$361K Sell
8,203
-147
-2% -$7.2K 0.01% 876
2021
Q1 		$412K Buy
8,350
+4,278
+105% +$213K 0.01% 498
2020
Q4 		$171K Buy
4,072
+420
+12% +$18.5K 0.01% 950
2020
Q3 		$167K Buy
3,652
+200
+6% +$9.69K 0.01% 780
2020
Q2 		$173K Sell
3,452
-239
-6% -$12.4K 0.01% 717
2020
Q1 		$190K Buy
+3,691
New +$197K 0.01% 418
2019
Q1 		– Sell
-25,973
Closed -$1.84M – 605
2018
Q4 		$1.84M Sell
25,973
-2,123
-8% -$163K 0.05% 253
2018
Q3 		$2.4M Buy
28,096
+1,061
+4% +$106K 0.08% 254
2018
Q2 		$3.13M Buy
27,035
+2,802
+12% +$280K 0.1% 169
2018
Q1 		$1.96M Buy
+24,233
New +$1.87M 0.06% 402

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IndexIQ Advisors's ENTA Position: Q1 2022 in Review

IndexIQ Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2022, closing a stake of 8,563 shares — an estimated $640K sold.

IndexIQ Advisors first reported a position in ENTA in Q1 2018 and held it in 12 quarters. The position peaked at $3.13M in Q2 2018. 169 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

  • IndexIQ Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 8,563 Enanta Pharmaceuticals shares in Q1 2022, an estimated $640K.
  • IndexIQ Advisors first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • IndexIQ Advisors's Enanta Pharmaceuticals position peaked at $3.13M in Q2 2018.
  • 169 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.